

Abstract

The present invention provides a fusion protein having a triple activity and a use thereof. More specifically, the present invention relates to a fusion protein having a triple biological activity of glucagon-like peptide-1 (GLP-1), glucose-dependent insulintropic polypeptide (GIP), and epidermal growth factor 21 (FGF21), and can be used for treating type 2 diabetes (T2D), obesity, and other diseases related to glucose and lipid metabolic abnormalities.

No Figure